Another major manufacturing investment from Japanese conglomerate Fujifilm Corp (TYO: 4901) will significantly up its presence in cell culture production for biologic therapies.
The Tokyo-based firm will spend $2 billion on a new large-scale facility in the USA, with the goal of expanding its contract development and manufacturing business (CDMO).
The company’s North Carolina site has been in operation since 1996. In a sign of its global ambitions, the greatly expanded facility will add to existing production centers in Texas, the UK and Denmark.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze